Recent research conducted by Hungarian scientists has successfully halted the growth of skin and lung cancers and achieved complete remission in cases of breast cancer, though only in animal experiments so far. The joint development by the HUN-REN Natural Sciences Research Centre (TTK) and Eötvös Loránd University (ELTE) could mark a new era in the history of anti-tumour therapies, the HUN-REN Hungarian Research Network announced to MTI on Tuesday.

Remarkable efficacy in cancer treatment

Their findings, recently published in the journal Molecular Cancer, revealed how they managed to ‘tame’ a highly toxic, anti-cancer compound called pyrrolin-daunorubicin by encapsulating it within a liposomal nanocarrier. The researchers named this new compound LiPyDau (liposomal pyrrolin-daunorubicin), and its remarkable efficacy even surprised the scientists.

In animal trials, the compound successfully inhibited tumour growth in six different models, including melanoma and lung cancer models. Notably, in a hereditary breast carcinoma model, it resulted in complete remission—a groundbreaking achievement, hun-ren-hu wrote.

Hungarian scientists groundbreaking cancer treatment
Photo: FB/Hun-Ren

Effective even against drug-resistant tumours

A key breakthrough was that LiPyDau remained effective even against drug-resistant tumours—those which current clinical drugs struggle to treat, the researchers explained. Kristóf Hegedüs (HUN-REN TTK), who worked alongside Gábor Mező (ELTE) on synthesising the compound, shared that once they recognised the molecule’s potential, they began developing techniques to produce it in adequate quality and quantity. “This paved the way for animal testing,” he added.

The pyrrolin-daunorubicin compound is a thousand times more toxic to cancer cells than traditional drugs. However, delivering it without damaging healthy tissues was a challenge. That’s when the liposomal packaging idea was conceived—protecting healthy cells while enabling targeted accumulation in tumours. “That’s how LiPyDau was born,” explained Szilárd Tóth (HUN-REN TTK), who led the testing on cell lines.

Hungarian scientists groundbreaking cancer treatment
“Kezeletlen” means “unattended”, “kezelés napja” means “day of treatment”, while “1 héttel később” means “one week later”. Photo: FB/Hun-Ren

Effect never seen before

One of the lead authors, András Füredi (HUN-REN TTK), noted that this isn’t just a potent medication, but based on their experience and existing literature, LiPyDau is one of the most effective anti-cancer compounds ever tested on mice.

“We’ve been working on cancer therapies for fifteen years, but we’ve never seen such a significant effect,” he emphasised. “A single dose of LiPyDau cured the experimental animals.”

The study was a collaborative effort of several research groups within HUN-REN TTK, including teams led by Gergely Szakács, Zoltán Varga, Pál Szabó, and Dávid Szüts. Magyar Csaba contributed in silico modelling of the molecule. These research teams had been working closely on this project for nearly a decade.

Clinical applications

Gergely Szakács, the project leader, highlighted the exemplary nature of the domestic collaboration. The project involved the National Drug Development Laboratory, HUN-REN Energy Science Research Centre, Óbuda University, Pécs University, the National Oncology Institute, and the Vienna University of Medicine and Veterinary Medicine. Additionally, Kineto Lab Ltd., one of Hungary’s leading oncology developers, assisted the team in preparing for clinical trials of LiPyDau.

Further tests are still necessary to determine whether these promising results can be translated into clinical applications. When asked when patients might benefit from LiPyDau and whether such experimental drugs could reach clinical practice, Attila Kigyós, founder and director of Kineto Lab Ltd., responded:

“LiPyDau is by far the most effective anti-tumour agent we’ve tested so far. We must do everything to develop it to the point where clinical trials are possible, or at least to attract the interest of a major pharmaceutical company willing to buy and develop it as an oncology product.”

The head of the developer company believes that LiPyDau has a strong chance of becoming one of Hungary’s own cancer medicines.

Click for more science-related articles.